A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Sponsor: Kumquat Biosciences Inc.
This PHASE1 trial investigates Solid Tumor, Adult and is currently actively recruiting participants. Kumquat Biosciences Inc. leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kumquat Biosciences Inc.
For direct contact, visit the study record on ClinicalTrials.gov .